Stockscreener 앱 받기
61.45
2.85%
-1.805
시간 외 거래:
61.46
0.005
+0.01%
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects - MSN
ANI Pharma stock wins J.P. Morgan bullish view (ANIP:NASDAQ) - Seeking Alpha
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone - Nasdaq
JPMorgan Initiates ANI Pharmaceuticals at Overweight With $85 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Buy” by Analysts - Defense World
ANI Pharmaceuticals Discusses Alimera Acquisition Challenges - TipRanks
Ani Pharmaceuticals’ chief HR officer Krista Davis sells $60,860 in stock - Investing.com Canada
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
Don't Ignore The Insider Selling In ANI Pharmaceuticals - Simply Wall St
Top Executive at ANI Pharmaceuticals Sells Thousands in Stock! - TipRanks
Ani Pharmaceuticals SVP sells $323,049 in stock By Investing.com - Investing.com UK
ANI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Q1 Earnings Estimate for ANIP Issued By HC Wainwright - Defense World
ANI Pharma at Raymond James Conference: Strategic Shift to Rare Diseases - Investing.com Canada
Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific - MSN
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Nasdaq
Rhumbline Advisers Trims Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Principal Financial Group Inc. Acquires 3,816 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to Sell - Defense World
ANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at HC Wainwright - Defense World
ANI Pharmaceuticals Reports Record 2024 Results and Raises 2025 Guidance - TipRanks
ANI Pharmaceuticals Gets FDA Approval for Cortrophin Gel in Prefilled Syringe Format as MS Therapy - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe - Marketscreener.com
ANI Pharmaceuticals Expands Treatment Options: FDA Greenlights Cortrophin Gel Prefilled Syringes - StockTitan
Truist maintains hold on ANI Pharmaceuticals, keeps $62 target - Investing.com India
ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance - GlobeNewswire
ANI Pharmaceuticals Reports Record Growth and Raises 2025 Outlook - TipRanks
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today By Stock Story - Investing.com Canada
Sector Update: Health Care Stocks Softer Friday Afternoon -February 28, 2025 at 01:50 pm EST - Marketscreener.com
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2024 - Marketscreener.com
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
ANI Pharmaceuticals stock surges 12% on strong Q4 results, raised guidance By Investing.com - Investing.com South Africa
ANI Pharmaceuticals stock surges 12% on strong Q4 results, raised guidance - Investing.com Australia
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast - Benzinga India
Earnings call transcript: ANI Pharmaceuticals beats Q4 2024 forecasts, stock up 10% - Investing.com
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ANI Pharmaceuticals, Inc. Reports Intangible Asset Impairment Charge for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Sector Update: Health Care Stocks Steady Pre-Bell Friday -February 28, 2025 at 09:07 am EST - Marketscreener.com
ANI Pharma rises as rare-disease drugs drive quarterly results beat - TradingView
ANI Pharmaceuticals Files Form 8-K with SEC - TipRanks
ANI: Q4 Earnings Snapshot - Thehour.com
ANI Pharma Raises FY25 Revenue Outlook; Stock Up 8%Update - Nasdaq
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results - TradingView
ANI Pharmaceuticals Q4 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
(ANIP) ANI Pharmaceuticals Sees Fiscal Year 2025 Revenue Range $756M$776M - Marketscreener.com
Earnings Flash (ANIP) ANI Pharmaceuticals Posts Q4 Revenue $190.6M, vs. FactSet Est of $175.4M - Marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars - Yahoo Finance
BRIEF-ANI Pharmaceuticals Q4 Revenue USD 87.043 Million Vs. IBES Estimate USD 175.4 Million - TradingView
ANI Pharmaceuticals Crushes Earnings Expectations: Is This Pharma Stock Ready for a Breakout? - StockTitan
ANI Pharmaceuticals Q4 2024 Earnings Preview - MSN
Allspring Global Investments Holdings LLC Has $323,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt? - Simply Wall St
0.77%
0.63%
자본화:
|
볼륨(24시간):